Bob Kronemyer

Freelance writer for Contemporary OB/GYN

Articles by Bob Kronemyer

In June 2021, ibrexafungerp (Brexafemme; Scynexis) became the first drug approved by the U.S. Food and Drug Administration (FDA) in a novel antifungal class in more than 20 years and is now available to treat vulvovaginal candidiasis (VVC).

A call to action in the journal Reproductive Sciences hopes to empower health care providers to optimize their quality of care for women with uterine fibroids by relying on the best available evidence and best patient-centered practices.

The use of labor neuraxial analgesia for vaginal delivery was associated with a 14% decrease in the risk of severe maternal morbidity (SMM), including postpartum hemorrhage (PPH), compared to vaginal delivery without neuraxial analgesia, according to a study published in JAMA Network Open.

An integrated model for prenatal care that incorporates both virtual and in-person visits has been well-received by patients and health care providers alike, according to a review in the Journal of Midwifery & Women’s Health.

Prenatal attachment levels were enhanced among pregnant women who were pleased with their appearance and body, displayed a positive attitude about their physical fitness, and engaged in practices that bolstered their health and physical capacity, according to a study in the Journal of Obstetric, Gynecologic & Neonatal Nursing.

Women with bacterial vaginosis (BV) and/or vulvovaginal candidiasis (VVC) were significantly less likely to use intimate soap and moist wipes after urination compared to healthy women without any vulvovaginal symptoms, according to a cross-sectional study published in the journal Revista Brasileira de Ginecologia e Obstetricia.

Women with laparoscopically confirmed endometriosis are at significantly higher risk for early natural menopause (ENM), and this risk was greater for nulliparous women and women who never reported using oral contraceptives, according to a study in JAMA Network Open.

A quality improvement study in JAMA Network Open has found that a significantly lower percentage of patients with breast cancer presented with stage I disease before the COVID-19 pandemic, in 2019, compared to after the start of the pandemic, in 2020.

Risk factors for the dual burden of severe maternal morbidity and preterm birth differ significantly by insurance type across sociodemographic and perinatal considerations in the state of California, according to a study in the Maternal and Children Health Journal.

Patients with acute vulvovaginal candidiasis (VVC) greatly benefited from oral ibrexafungerp (Brexafemme, Scynexis), according to results of a global phase 3 randomized, double-blind, placebo-controlled superiority study published in the international journal of obstetrics and gynecology, BJOG.